Literature DB >> 16362768

Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.

Kirill O Eremin1, Vladimir S Kudrin, Pirjo Saransaari, Simo S Oja, Igor A Grivennikov, Nikolay F Myasoedov, Kirill S Rayevsky.   

Abstract

Corticotrophin (ACTH) and its analogues, particularly Semax (Met-Glu-His-Phe-Pro-Gly-Pro), demonstrate nootropic activity. Close functional and anatomical links have been established between melanocortinergic and monoaminergic brain systems. The aim of present work was to investigate the effects of Semax on neurochemical parameters of dopaminergic- and serotonergic systems in rodents. The tissue content of 5-hydroxyindoleacetic acid (5-HIAA) in the striatum was significantly increased (+25%) 2 h after Semax administration. The extracellular striatal level of 5-HIAA gradually increased up to 180% within 1-4 h after Semax (0.15 mg/kg, ip) administration. This peptide alone failed to alter the tissue and extracellular concentrations of dopamine and its metabolites. Semax injected 20 min prior D: -amphetamine dramatically enhanced the effects of the latter on the extracellular level of dopamine and on the locomotor activity of animals. Our results reveal the positive modulatory effect of Semax on the striatal serotonergic system and the ability of Semax to enhance both the striatal release of dopamine and locomotor behavior elicited by D-amphetamine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16362768     DOI: 10.1007/s11064-005-8826-8

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  37 in total

Review 1.  Pharmacological findings contribute to the understanding of the main physiological mechanisms of memory retrieval.

Authors:  Daniela M Barros; Luciana A Izquierdo; Jorge H Medina; Ivan Izquierdo
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2003-04

2.  Role of the mesotelencephalic dopamine system in learning and memory processes in the rat.

Authors:  Vasile Hefco; Kiyofumi Yamada; Andreea Hefco; Lucian Hritcu; Adrian Tiron; Toshitaka Nabeshima
Journal:  Eur J Pharmacol       Date:  2003-08-15       Impact factor: 4.432

3.  Effects of ACTH and ACTH 4-10 on aversive memory retrieval in rats.

Authors:  K B Kumar; K S Karanth
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 4.  Melanocortins and the brain: from effects via receptors to drug targets.

Authors:  R A Adan; W H Gispen
Journal:  Eur J Pharmacol       Date:  2000-09-29       Impact factor: 4.432

5.  Signalling pathways involved in the short-term potentiation of dopamine release by BDNF.

Authors:  Julian Goggi; Ian A Pullar; Stephen L Carney; Henry F Bradford
Journal:  Brain Res       Date:  2003-04-04       Impact factor: 3.252

6.  Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.

Authors:  Shigeyuki Chaki; Shiho Hirota; Takeo Funakoshi; Yoshiko Suzuki; Sayoko Suetake; Taketoshi Okubo; Takaaki Ishii; Atsuro Nakazato; Shigeru Okuyama
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

7.  Characterization of the inhibitory effect of adrenocorticotropin/melanocyte-stimulating hormone-like peptides on the binding of dopamine receptor ligands to the dopamine D2 receptor in vitro.

Authors:  W J Florijn; T De Boer; J A Tonnaer; D H Versteeg
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

Review 8.  Role of neurotrophic factors in the etiology and treatment of mood disorders.

Authors:  Ronald S Duman
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

9.  Identification of antagonists for melanocortin MC3, MC4 and MC5 receptors.

Authors:  R A Adan; J Oosterom; G Ludvigsdottir; J H Brakkee; J P Burbach; W H Gispen
Journal:  Eur J Pharmacol       Date:  1994-11-15       Impact factor: 4.432

10.  Exercise, antidepressant treatment, and BDNF mRNA expression in the aging brain.

Authors:  Antonio A Garza; Tony G Ha; Celithelma Garcia; Michael J Chen; Amelia A Russo-Neustadt
Journal:  Pharmacol Biochem Behav       Date:  2004-02       Impact factor: 3.533

View more
  6 in total

1.  Expression changes caused by the peptide semax in the intracellular signal pathway genes in rat hippocamp.

Authors:  T Yu Agapova; Ya V Agniullin; D N Silachev; M I Shadrina; P A Slominsky; S I Shram; S A Limborskaya; N F Myasoedov
Journal:  Dokl Biochem Biophys       Date:  2007 Nov-Dec       Impact factor: 0.788

2.  Semax corrects brain dysfunction caused by prenatal introduction of valproic acid.

Authors:  A V Malyshev; E V Razumkina; V A Dubynin; N F Myasoedov
Journal:  Dokl Biol Sci       Date:  2013-07-03

3.  Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action.

Authors:  Maria Shadrina; Timur Kolomin; Tamara Agapova; Yan Agniullin; Stanislav Shram; Petr Slominsky; Svetlana Lymborska; Nikolay Myasoedov
Journal:  J Mol Neurosci       Date:  2009-08-07       Impact factor: 3.444

4.  Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats.

Authors:  Ivan B Filippenkov; Vasily V Stavchansky; Alina E Denisova; Vadim V Yuzhakov; Larisa E Sevan'kaeva; Olga Y Sudarkina; Veronika G Dmitrieva; Leonid V Gubsky; Nikolai F Myasoedov; Svetlana A Limborska; Lyudmila V Dergunova
Journal:  Genes (Basel)       Date:  2020-06-22       Impact factor: 4.096

5.  Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion.

Authors:  Olga Yu Sudarkina; Ivan B Filippenkov; Vasily V Stavchansky; Alina E Denisova; Vadim V Yuzhakov; Larisa E Sevan'kaeva; Liya V Valieva; Julia A Remizova; Veronika G Dmitrieva; Leonid V Gubsky; Nikolai F Myasoedov; Svetlana A Limborska; Lyudmila V Dergunova
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

6.  Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease.

Authors:  Vladimir Khavinson; Anastasiia Ilina; Nina Kraskovskaya; Natalia Linkova; Nina Kolchina; Ekaterina Mironova; Alexander Erofeev; Michael Petukhov
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.